MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year |
Group, Inc. (the Company) held on December 14, 2016, the Board
approved and adopted effective as of such date an amendment (the
Amendment) to the Bylaws, as amended, of the Company amending
Article II, Section 8 of the Bylaws to provide for majority
voting in uncontested elections of directors.
a majority of votes cast at the meeting will be required to
promptly tender a letter of resignation to the Board and the
Nominating and Corporate Governance Committee of the Board will
make a recommendation to the Board on whether to accept or reject
the resignation, or whether other action should be taken. Taking
into account the recommendation of the Nominating and Corporate
Governance Committee, the Board will make a determination
regarding the resignation within 100 days from the date of the
certification of election results.
complete and is qualified in its entirety by reference to the
full text of the Amendment, attached hereto as Exhibit 3.1 and
incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
(c)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
3.1
|
Amendment to the Bylaws of MiMedx Group, Inc. adopted
by the Board of Directors on December 14, 2016 |
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts. MIMEDX GROUP, INC. (NASDAQ:MDXG) Recent Trading Information
MIMEDX GROUP, INC. (NASDAQ:MDXG) closed its last trading session up +0.29 at 8.96 with 941,784 shares trading hands.
